NASDAQ:AFMD Affimed (AFMD) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free AFMD Stock Alerts $4.54 -0.03 (-0.66%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$4.51▼$5.0450-Day Range$0.61▼$6.9052-Week Range$2.23▼$11.10Volume100,286 shsAverage Volume92,919 shsMarket Capitalization$67.78 millionP/E RatioN/ADividend YieldN/APrice Target$53.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Affimed alerts: Email Address Affimed MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside1,074.7% Upside$53.33 Price TargetShort InterestHealthy1.19% of Float Sold ShortDividend StrengthN/ASustainability-1.95Upright™ Environmental ScoreNews Sentiment0.80Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($7.72) to ($5.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.58 out of 5 starsMedical Sector98th out of 947 stocksPharmaceutical Preparations Industry39th out of 435 stocks 3.4 Analyst's Opinion Consensus RatingAffimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.33, Affimed has a forecasted upside of 1,074.7% from its current price of $4.54.Amount of Analyst CoverageAffimed has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.19% of the float of Affimed has been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Affimed has recently decreased by 89.86%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAffimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.Environmental SustainabilityThe Environmental Impact score for Affimed is -1.95. Previous Next 3.8 News and Social Media Coverage News SentimentAffimed has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Affimed this week, compared to 1 article on an average week.Search Interest8 people have searched for AFMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows7 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Affimed is held by insiders.Percentage Held by InstitutionsOnly 30.82% of the stock of Affimed is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Affimed are expected to grow in the coming year, from ($7.72) to ($5.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Affimed is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Affimed is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAffimed has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Affimed Stock (NASDAQ:AFMD)Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.Read More AFMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AFMD Stock News HeadlinesMarch 17, 2024 | americanbankingnews.comAffimed (NASDAQ:AFMD) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarch 14, 2024 | americanbankingnews.comAffimed (NASDAQ:AFMD) Sees Large Volume IncreaseMarch 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 13, 2024 | seekingalpha.comJefferies starts Cue at buy, cites partnering potentialMarch 13, 2024 | americanbankingnews.comAffimed (NASDAQ:AFMD) Shares Gap Down to $6.08March 13, 2024 | americanbankingnews.comShort Interest in Affimed (NASDAQ:AFMD) Drops By 89.9%March 8, 2024 | msn.comWhy Is Affimed (AFMD) Stock Moving Today?March 8, 2024 | investorplace.comWhy Is Affimed (AFMD) Stock Moving Today?March 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 7, 2024 | msn.comVaxxinity gains after early-stage data for Parkinson’s disease drugMarch 6, 2024 | finanznachrichten.deAffimed N.V.: Affimed Announces 1-for-10 Reverse Stock SplitMarch 6, 2024 | msn.comAffimed falls on 1-for-10 reverse stock splitMarch 6, 2024 | investorplace.com7 of the Best Speculative Stocks You Can Snag for Less Than $1March 6, 2024 | globenewswire.comAffimed Announces 1-for-10 Reverse Stock SplitJanuary 9, 2024 | marketwatch.comAffimed CEO Adi Hoess Steps Down; Co to Cut Up to 50% of WorkforceJanuary 9, 2024 | finanznachrichten.deAffimed N.V.: Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerJanuary 8, 2024 | marketwatch.comAffimed N.V. to Expand Cohort in Study of AFM24 Following Promising DataJanuary 8, 2024 | finance.yahoo.comAffimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerJanuary 8, 2024 | finance.yahoo.comAffimed Announces Leadership Change and Organizational RestructuringJanuary 3, 2024 | finanznachrichten.deAffimed N.V.: Affimed Announces Sale of Wholly-Owned Subsidiary AbCheckJanuary 3, 2024 | finance.yahoo.comAffimed Announces Sale of Wholly-Owned Subsidiary AbCheckDecember 14, 2023 | markets.businessinsider.comBuy Rating Reaffirmed for Affimed as Promising Clinical Trials Propel OptimismDecember 11, 2023 | msn.comAffimed erases gains despite positive trial dataDecember 4, 2023 | finance.yahoo.comAffimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24November 30, 2023 | msn.comAffimed slips as finance chief and science chief departNovember 20, 2023 | markets.businessinsider.comPromising Investment Potential in Affimed’s Stock: Harnessing Clinical Trials for Lymphoma Treatment and FDA Meeting ResolutionNovember 20, 2023 | finance.yahoo.comAffimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call TranscriptSee More Headlines Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/18/2024Next Earnings (Estimated)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AFMD CUSIPN/A CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees219Year FoundedN/APrice Target and Rating Average Stock Price Target$53.33 High Stock Price Target$70.00 Low Stock Price Target$10.00 Potential Upside/Downside+1,074.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($8.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,610,000.00 Net Margins-638.68% Pretax Margin-641.56% Return on Equity-104.40% Return on Assets-75.85% Debt Debt-to-Equity Ratio0.10 Current Ratio3.70 Quick Ratio3.67 Sales & Book Value Annual Sales$43.58 million Price / Sales1.56 Cash FlowN/A Price / Cash FlowN/A Book Value$13.05 per share Price / Book0.35Miscellaneous Outstanding Shares14,930,000Free Float14,367,000Market Cap$67.78 million OptionableOptionable Beta2.07 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Andreas Harstrick M.D. (Age 63)Interim CEO, Chief Medical Officer & Member of Management Board Comp: $537.52kDr. Wolfgang Fischer (Age 60)MD, COO & Member of Management Board Comp: $648.51kMs. Denise Mueller (Age 54)Chief Business Officer & Member of Management Board Comp: $631.1kProf. Melvyn LittleFounder & ConsultantMr. Michael Wolf (Age 57)Head of Finance & Administration Mr. Alexander FudukidisHead of Investor Relations & Director of Investor RelationsMary Beth SandinVice President of Marketing & CommunicationsMore ExecutivesKey CompetitorsSilence TherapeuticsNASDAQ:SLNAstria TherapeuticsNASDAQ:ATXSPharming GroupNASDAQ:PHARZymeworksNYSE:ZYMEAcelyrinNASDAQ:SLRNView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 1,200 shares on 2/15/2024Ownership: 0.000%Verition Fund Management LLCSold 122,032 shares on 2/14/2024Ownership: 0.647%Vestal Point Capital LPBought 546,067 shares on 2/14/2024Ownership: 0.366%BNP Paribas Financial MarketsBought 163,162 shares on 2/7/2024Ownership: 0.383%EWA LLCBought 142,525 shares on 2/5/2024Ownership: 0.095%View All Institutional Transactions AFMD Stock Analysis - Frequently Asked Questions Should I buy or sell Affimed stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AFMD shares. View AFMD analyst ratings or view top-rated stocks. What is Affimed's stock price target for 2024? 6 Wall Street research analysts have issued 1 year price objectives for Affimed's shares. Their AFMD share price targets range from $10.00 to $70.00. On average, they predict the company's share price to reach $53.33 in the next year. This suggests a possible upside of 1,074.7% from the stock's current price. View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts. How have AFMD shares performed in 2024? Affimed's stock was trading at $6.25 at the start of the year. Since then, AFMD stock has decreased by 27.4% and is now trading at $4.54. View the best growth stocks for 2024 here. Are investors shorting Affimed? Affimed saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 155,100 shares, a decrease of 89.9% from the February 14th total of 1,530,000 shares. Based on an average trading volume of 113,600 shares, the days-to-cover ratio is presently 1.4 days. Approximately 1.2% of the company's shares are short sold. View Affimed's Short Interest. When is Affimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AFMD earnings forecast. How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) announced its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by $0.10. The biopharmaceutical company had revenue of $10.21 million for the quarter, compared to the consensus estimate of $11.79 million. Affimed had a negative net margin of 638.68% and a negative trailing twelve-month return on equity of 104.40%. During the same quarter in the prior year, the business earned ($0.80) EPS. When did Affimed's stock split? Affimed's stock reverse split before market open on Monday, March 11th 2024. The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN). Who are Affimed's major shareholders? Affimed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Verition Fund Management LLC (0.65%), BNP Paribas Financial Markets (0.38%), Vestal Point Capital LP (0.37%), abrdn plc (0.14%), EWA LLC (0.10%) and Citadel Advisors LLC (0.00%). How do I buy shares of Affimed? Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AFMD) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.